A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Plain-language summary
This trial is testing Bexarotene for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 3 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Bexarotene (DRUG): Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study. | Total Skin Electron Beam (TSEB) (RADIATION): At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
Bexarotene, Total Skin Electron Beam (TSEB)
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details